Transgene Crecimiento futuro

Future controles de criterios 2/6

Transgene se prevé un crecimiento anual de los beneficios y los ingresos de 29.2% y 70.4%, respectivamente, mientras que el BPA aumentará de decline a 1.8%.

Información clave

29.2%

Tasa de crecimiento de los beneficios

-1.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	20.7%
Tasa de crecimiento de los ingresos	70.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	07 Jul 2023

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OTCPK:TRGN.F - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	50	-21	-20	N/A	1
12/31/2024	40	-14	-13	N/A	1
12/31/2023	7	-42	-13	N/A	1
6/30/2023	9	-33	N/A	N/A	N/A
3/31/2023	10	-33	N/A	N/A	N/A
12/31/2022	10	-33	-22	-20	N/A
9/30/2022	14	-28	-22	-21	N/A
6/30/2022	18	-23	-28	-27	N/A
3/31/2022	18	-21	-30	-30	N/A
12/31/2021	17	-20	-27	-26	N/A
9/30/2021	13	-23	-29	-28	N/A
6/30/2021	9	-27	-31	-30	N/A
3/31/2021	9	-22	-30	-29	N/A
12/31/2020	10	-17	-30	-29	N/A
9/30/2020	12	-11	-31	-30	N/A
6/30/2020	14	-6	-33	-31	N/A
3/31/2020	14	-12	-28	-27	N/A
12/31/2019	13	-19	-24	-22	N/A
9/30/2019	11	-6	-24	-23	N/A
6/30/2019	8	8	-23	-23	N/A
3/31/2019	8	8	-26	-25	N/A
12/31/2018	7	8	-29	-28	N/A
9/30/2018	7	-10	-31	-29	N/A
6/30/2018	7	-29	-32	-30	N/A
3/31/2018	7	-31	-34	-33	N/A
12/31/2017	7	-32	-36	-35	N/A
9/30/2017	8	-32	-36	-36	N/A
6/30/2017	9	-31	-37	-37	N/A
3/31/2017	9	-28	N/A	-35	N/A
12/31/2016	10	-24	N/A	-34	N/A
9/30/2016	10	-26	N/A	-37	N/A
6/30/2016	9	-28	N/A	-40	N/A
3/31/2016	9	-33	N/A	-43	N/A
12/31/2015	10	-38	N/A	-45	N/A
9/30/2015	10	-40	N/A	-48	N/A
6/30/2015	10	-42	N/A	-50	N/A
3/31/2015	11	-41	N/A	-52	N/A
12/31/2014	11	-41	N/A	-54	N/A
9/30/2014	13	-41	N/A	-52	N/A
6/30/2014	15	-41	N/A	-50	N/A
3/31/2014	15	-42	N/A	-50	N/A
12/31/2013	16	-43	N/A	-50	N/A
9/30/2013	15	-44	N/A	-48	N/A
6/30/2013	14	-45	N/A	-46	N/A
3/31/2013	13	-44	N/A	-48	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: TRGN.F se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: TRGN.F se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: TRGN.F se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: TRGN.FSe prevé que los ingresos de la empresa (70.4% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: TRGN.FSe prevé que los ingresos de la empresa (70.4% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de TRGN.F se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Transgene Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Transgene SA has completed a Follow-on Equity Offering in the amount of €34.1285 million.

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

Transgene SA Announces the Presentation of the Detailed Results from the Phase 1b/2 Trial Combining TG4001, a HPV16-Targeted Therapeutic Vaccine, with Avelumab (BAVENCIO®)

Transgene Announces Detailed Results from the Phase 1B/2 Trial Combining TG4001

Transgene Announces Detailed Results of the Data from the Phase 1b/2 Trial Combining TG4001

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

A Chinese Investment Fund acquired an unknown minority stake in Shanghai Tasly Pharmaceutical Co., Ltd from Transgene SA (ENXTPA:TNG) for $22.2 million.

Vaxxel SAS acquired DuckCelt®-T17 cell line of Transgene SA (ENXTPA:TNG).

Mediolanum Farmaceutici S.P.A. acquired ElsaLys Biotech SA.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento